Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin First-Line in Advanced Soft Tissue Sarcoma Patients Unfit for Standard Chemotherapy
2013-001467-23Phase 2Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Jun 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in soft tissue sarcoma (STS), sponsored by Italian Sarcoma Group. Primary endpoint: Progression-free survival rate at 3 months (PFS3). Started Jun 2013; status: completed.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2013-001467-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001467-23.